FORM PTO-1390 (REV 11-2000)	U.S. DEPARTMENT OF COMMERCE / PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 2548-17
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/889636
INTERNATIONAL APPLICATION NO. PCT/IB00/00133	INTERNATIONAL FILING DATE 7 February 2000	PRIORITY DATE CLAIMED 5 February 1999

TITLE OF INVENTION
CYCLOSPORIN DERIVATIVES AND METHOD FOR THE PRODUCTION OF SAID DERIVATIVES

APPLICANT(S) FOR DO/EO/US
MUTTER et al

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The U.S. has been elected by the expiration of 19 months from the priority date (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   b. ☒ has been communicated by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☒ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
   d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 To 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information. PTO-1449 and copy of International Search Report

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
09/890636 Unknown	PCT/IB00/00133	2548-17

21. ☒ The following fees are submitted:

	CALCULATIONS	PTO USE ONLY

BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):

-- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO $1000.00

-- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO $860.00

-- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO $710.00

-- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) $690.00

-- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) $100.00

ENTER APPROPRIATE BASIC FEE AMOUNT = $ 860.00

Surcharge of $130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)). $ 0.00

CLAIMS	NUMBER FILED		NUMBER EXTRA		RATE		
Total Claims	6	-20 =	0	X	$18.00	$	0.00
Independent Claims	1	-3 =	0	X	$80.00	$	0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)					$270.00	$	0.00
					TOTAL OF ABOVE CALCULATIONS =	$	**860.00**

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. 0.00

SUBTOTAL = $ **860.00**

Processing fee of $130.00, for furnishing the English Translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)). + 0.00

TOTAL NATIONAL FEE = $ **860.00**

Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). **$40.00** per property + $ 0.00

Fee for Petition to Revive Unintentionally Abandoned Application ($1240.00 – Small Entity = $620.00) $ 0.00

TOTAL FEES ENCLOSED = $ **860.00**

Amount to be: refunded $

Charged $

a. ☒ A check in the amount of $860.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 14-1140 in the amount of $_____ to cover the above fees. A duplicate copy of this form is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed.

d. ☒ The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.

NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

NIXON & VANDERHYE P.C.
1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000

SIGNATURE

Duane M. Byers
NAME

33,363 REGISTRATION NUMBER

August 3, 2001 Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MUTTER et al Atty. Ref.: **2548-17**

Serial No. **Unknown** Group:

National Phase of: **PCT/IB00/00133**
International Filing Date: **7 February 2000**

Filed: **August 3, 2001** Examiner:

For: **CYCLOSPORIN DERIVATIVES AND METHOD FOR THE PRODUCTION OF SAID DERIVATIVES**

* * * * * * * * * * *

August 3, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Prior to calculation of the filing fee and in order to place the above identified application in better condition for examination, please amend the claims as follows:

IN THE CLAIMS

Please substitute the following amended claim for the corresponding claim previously presented. A copy of the amended claim showing current revision is attached.

3. (Amended) The derivative according to Claim 1, characterized in that it is derived from a cyclosporin in which the peptide chain contains at least one amino acid, chosen from serine, threonine and Sistine, in d or l configuration.

Please add the following new claim:

6. (New) The derivative according to Claim 2, characterized in that it is derived from a cyclosporin in which the peptide chain contains at least one amino acid, chosen from serine, threonine and Sistine, in d or l configuration.

IN THE ABSTRACT

Please provide as the Abstract of the Disclosure what is provided on the attached sheet.

REMARKS

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version with markings to show changes made**."

The above amendments are made to place the claims in a more traditional format and to provide an Abstract of the Disclosure.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____

Duane M. Byers
Reg. No. **33,363**

DMB:lmy

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. (Amended) The derivative according to [any of the preceding Claims] Claim 1, characterized in that it is derived from a cyclosporin in which the peptide chain contains at least one amino acid, chosen from serine, threonine and Sistine, in d or l configuration.

ABSTRACT OF THE DISCLOSURE

The invention relates to cyclosporin derivatives, whereby the peptide chain thereof comprises at least one pseudo-proline type non-natural amino acid radical. The invention also relates to a method for the production of said derivatives.

Cyclosporin derivatives and method of preparing said derivatives

The present invention relates to cyclosporin derivatives in which the peptide sequence comprises at least one non-natural amino acid of the pseudo-proline type. It also relates to a method of preparing the said derivatives.

Cyclosporins constitute a family of secondary metabolites obtained by fermentation. These substances possess remarkable biological properties, including immuno-suppression, and the ability to induce nerve proliferation in neurodegenerative diseases or to stop replication of the HIV-1 virus. About thirty cyclosporins have so far been isolated from natural sources. The best known, on account of its use in organ transplantation, is Cyclosporin A (CsA). It was subsequently found that the same Cyclosporin A might open up new pathways in the treatment of AIDS by inhibiting activation of the $CD4^+$ cells.

Cyclosporins consist of a complex cyclic peptide sequence of eleven amino acids, some of these being non-natural amino acids that are frequently methylated on the nitrogen atom. These substances are strongly hydrophobic in character, which complicates their administration in a physiological medium.

At present, there is still a need to modify the structure in order to improve the biological activity and / or physicochemical properties of the existing cyclosporins, whether natural or synthetic.

One of the aims of the present invention, therefore, is to make available cyclosporin derivatives of natural or synthetic origin, in which the pharmacological specificity has been improved, preferably to favor inhibition of $CD4^+$ cell activation so as to stop replication of the HIV-1 virus.

Another aim of the present invention is to make available cyclosporin derivatives, of natural or synthetic origin, of which the physical properties have been modified so as to confer on them a certain hydrophilic character, in order to increase their solubility in a physiological medium and so to facilitate their administration.

The object of the present invention is therefore cyclosporin derivatives of natural or non-natural origin, in which the peptide chain of the said derivatives comprises at least one non-natural amino acid residue of general formula I:



(I)

in which

X represents an oxygen or sulfur atom;

R represents a hydrogen atom or an alkyl group containing between 1 and 6 carbon atoms, preferably a methyl group;

R_1 and R_2 represent, independently of each other, a hydrogen atom, an alkyl group, containing between 1 and 6 carbon atoms, that may be straight-chain or branched-chain, substituted or non-substituted, an alkylene group containing between 1 and 6 carbon atoms, a non-substituted aryl group such as phenyl, a substituted aryl group such as p-carbomethoxyphenyl or p-methoxyphenyl, or a substituted or non-substituted heteroaryl group.

R_1 and R_2 may also represent a residue of a water-soluble polymer, possibly bound to a spacer group. Suitable examples of such a polymer include polyalkylene oxides (PAO) such as polyethylene glycols, polyvinyl alcohols, and carbohydrate-based polymers. The water-soluble polymer is preferably a polyalkylene oxide, such as a polyethylene glycol. The spacer

group may be an alkyl group containing between 1 and 6 carbon atoms, an aryl group such as phenyl, or a heteroaryl, each carrying a functional group permitting anchoring to the polymer. If the polymer is a polyethylene glycol the preferred spacer group is p-carboxyphenylene.

The generic name "pseudo-proline" has been given in the present application to the non-natural amino acid of general formula I, and the abbreviations Ser($\psi^{R1,R2}$pro), Thr($\psi^{R1,R2}$pro) and Cys($\psi^{R1,R2}$pro) indicate that, in the general formula I, the symbols (X, R) represent respectively (O, H), (O, Me) and (S, H), and that the amino acid is derived respectively from serine, threonine and cysteine.

The cyclosporin derivatives of the present invention are preferably derived from natural or synthetic cyclosporins in which the peptide chain contains at least one of the following amino acids in the d or l configuration: serine, threonine or cysteine. In the peptide sequence of the cyclosporin derivatives of the present invention, at least one of the amino acids serine, threonine or cysteine, in the d or l configuration, of the basic cyclosporins has been replaced by a non-natural amino acid of general formula I.

On account of the complexity of the peptide chain of the cyclosporins, any chemical modification of their structure rapidly becomes complicated. For this reason, a total synthesis is not considered suitable.

Therefore, another aim of the present invention is to provide the simplest possible preparative method for these cyclosporin derivatives, using starting materials, both cyclosporins and reagents, which are easily available.

Thus the object of the present invention is also to provide a method of preparation of cyclosporin derivatives in which the peptide chain comprises at least one of the amino acids serine, threonine and cysteine, by N,O-acetalisation of at least one of the three above-mentioned amino

acids. This is done by bringing the cyclosporin into contact with a compound of formula II:



(II)

in which

Z_1 and Z_2 represent, independently of each other, a halogen, a hydroxyl group, an alkoxy group, a thiol; or

both Z_1 and Z_2 represent either an oxygen of a carbonyl group or a sulfur of a thione; and

R_1 and R_2 have the same definition as above.

The compound of formula II is preferably an acetal or thioacetal.

The properties of the cyclosporin derivatives of the present invention, the advantages offered by them, and the detailed method of preparation of these derivatives will be illustrated using the specific examples below, and with the help of the drawing, in which

- Fig. 1 shows the synthetic scheme for the synthesis of a cyclosporin derivative;
- Fig. 2 shows the synthetic scheme for synthesis of an intermediate in the preparation of the derivative of Fig. 1;
- Fig. 3 shows HPLC chromatograms over a period of time in a hydrolysis test of a cyclosporin derivative;
- Fig. 4 is a curve showing the variation with time of the concentration of the products in the same hydrolysis test; and

– Fig. 5 is a curve showing the kinetics of inhibition, by a cyclosporin derivative, of cis-trans isomerase activity in Cyclophilin A from calf thymus.

Three cyclosporins served as the starting materials for preparation of the derivatives by the method of the invention. Two of these cyclosporins are of natural origin. These are Cyclosporin A (CsA) and Cyclosporin C (CsC). The third cyclosporin, [D-Ser^{8}]Cyclosporin A, is obtained by fermentation with incorporation of the amino acid D-serine, according to the method described by Traber et al. in *The Journal of Antibiotics, 1989.*

Two series of experiments were performed, depending on the nature of the cyclosporin derivatives prepared. The first series of experiments was directed towards modification of the physical properties of the cyclosporins, and particularly towards the conferring of hydrophilic character. The second series focused on improvement of their biological properties.

In this connection, it is known from well-established structure-activity studies that the continuous peptide moiety in Cyclosporin A constituted by the amino acids in positions 10 to 11, 1 to 3 (the numbering system takes the amino acid MeBmt as position 1) binds to cyclophilin (CyP), a protein having peptidylprolyl cis-trans isomerase activity. The free peptide part then binds to calcineurin (Cn) and the complex so formed [(CsA-CyP)-Cn] is responsible for immuno-suppression, as it inhibits transcription of the essential genes of the cytokines. The structure of Cyclosporin C is distinguished from that of Cyclosporin A by the amino acid in position 2, which is Ser instead of Abu. Its mode of action is similar, however.

1. Preparation of the derivatives of Cyclosporin A, i.e., [5-L-Thr($\psi^{R1,R2}$pro)]CsA of general formula III:



(III)

In derivatives of Cyclosporin A of general formula III, pseudo-proline L-Thr($\psi^{R1,R2}$pro) occupies position 5, thus substituting the valine of Cyclosporin A.

This is achieved by opening the Cyclosporin A ring by cleavage of the 4-5 peptide bond. The 7-8 peptide bond is then cleaved in turn. After the protection and activation stages the dipeptide Fmoc-NMeLeu-L-Thr($\psi^{R1,R2}$pro)-OH, prepared previously, is bound to the aminoacid Ala in position 7; the peptide ring is then again closed, giving the [5-L-Thr(($\psi^{R1,R2}$pro)]CsA derivatives of Cyclosporin A.

The derivatives of formula IIIa and IIIb were prepared by reaction with the appropriate Fmoc-NMeLeu-L-Thr($\psi^{R1,R2}$pro)-OH dipeptide.

Derivative	R_1	R_2
IIIa	H	MeO-PEG 750-NHCO-phenyl-
IIIb	Me	Me

The synthetic schemes for the synthesis of derivative IIIa, and of one of the intermediates in this synthesis, the dipeptide Fmoc-NMeLeu-L-Thr(ψ $^{MeO\text{-}PEG\ 750\text{-}NHCO\text{-}phenyl\text{-},\ H}$ pro)-OH, are shown in detail in Figures 1 and 2. It appears that such a procedure, involving opening of the Cyclosporin A ring, insertion of a peptide containing the appropriate pseudo-proline, and ring closure, although it yields the derivatives of the present invention, is not suitable, on account of its complexity, for preparation of a large number of derivatives and on a large scale.

We give below practical details of the method of preparation of cyclosporin derivatives in the present invention. This uses as the starting material a cyclosporin in which the peptide chain comprises at least one of the amino acids serine, threonine and cysteine.

In a single stage involving an N,O-acetalisation of at least one of the three above-mentioned amino acids, using an appropriate compound of formula II above, a cyclosporin derivative is obtained, in which pseudo-proline has replaced one of the amino acids serine, threonine or cysteine of the starting cyclosporin.

2. Preparation of L-Thr($\psi^{R1,R2}$pro)]CsC derivatives of Cyclosporin C having the general formula IV:



(IV)

The derivatives IVa to IVh were prepared by the following general method.

A mixture of anhydrous Cyclosporin C (CsC) (50 mg, 41 μmol), dimethylacetal $R_1R_2C(OMe)_2$ (205 μmol, 5 eq) and pyridinium salt of p-toluenesulfonic acid (4.0 mg, 0.4 eq, PPTS) in anhydrous toluene (4 ml) is brought to reflux. When the reaction is complete, the organic phase is washed with Na_2CO_3 (10%, 2x5 ml) and water (2x5 ml), and dried over magnesium sulfate. The organic phase is concentrated under reduced pressure to yield an oil. The crude product is dissolved in 2 ml of an acetonitrile / water mixture (1:1 v/v) and purified by reverse-phase HPLC (C_{18}, 60 – 100% B, 40 min.). Lyophilisation gives the Cyclosporin C derivative as a white powder.

Derivative	R_1	R_2	Reaction time (min.)	Yield (%)	Mass (calc.) found m/z
IVa	H	Ph-	45	74	(1306.7) 1306.7
IVb	H	Ph-Ph-	30	89	(1382.8) 1383.8
IVc	H	CH2=CH-	60	75	(1256.7) 1257.7
IVd	H	*p*-CO_2Me-Ph-	120	55	(1364.7) 1364.7
IVe	H	*p*-OMe-Ph-	60	90	(1336.2) 1337.2
IVf	H	*p*-AllOOC-Ph-	50	95	(1390.7) 1391
IVg	H	*p*-HOOC-PhCH$(OMe)_2$	50[d]	75	(1350.7) 1351
IVh	H	PEG[350]-CH-	240	20	(~ 1851) ~1851[e]

3. Preparation of D-Ser^8($\psi^{R1,R2}$pro)]CsA derivatives of D-Ser^8-Cyclosporin A of general formula V:



(V)

The derivatives Va to Ve were prepared by the following general method.

A mixture containing (anhydrous) Cyclosporin D-Ser^8-CsA (1 eq.), dimethylacetal $R_1R_2C(OCH_3)_2$ (10 eq.), PPTS (pyridinium salt of p-toluenesulfonic acid) (0.4 eq.) and anhydrous DMSO (0.016 M) is heated to 100 °. The reaction mixture is poured into 150 ml of AcOEt. The organic phase is washed successively with a saturated solution of $NaHCO_3$ (3 times) and a saturated solution of NaCl (once), dried over Na_2SO_4 and concentrated. The crude product is purified by chromatography on silica gel (acetone / hexane, 4/6) to give a white powder.

Derivative	R_1	R_2	Reaction time	Yield (%)	Rf (acetone / hexane) (4/6)	HPLC in minutes	Mass ESI-MS
Va	CH_3	CH_3	3 h	58	0.25	17.98	1244/1276 /1293
Vb	$-CH_2OAc$	H	30 h	74	0.32	18.65	1334/1351
Vc	$-(CH_2)$-NH-Fmoc	H	2 h	70	0.25	17.96	1509/1526
Vd	-Ph	H	3 h	72	0.50	19.16	1306/1323 /1328
Ve	-p-Ph-CH_2-NH-Aloc	H	20 mn	67	0.54	19.42	1419/1436

4. Physical properties of the cyclosporin derivatives of the present invention.

4.1 Preparation of prodrugs

Surprisingly, it has been found that introduction of a pseudo-proline within the cyclosporin chain allows preparation of a prodrug of the same cyclosporin.

The chemical stability of the derivatives of the present invention, particularly under acid hydrolysis conditions, has been studied as a function of the type of groups in the para position of the phenyl ring of the substituent R_1 or R_2. Electron-withdrawing groups stabilize the oxazolidine ring of the pseudo-proline. On the other hand, electron-donating groups, such as the methoxy group, make the pseudo-proline extremely sensitive to acid media and, in a reversible reaction, the oxazolidine ring opens, releasing the serine or threonine of the initial cyclosporin.

For example, derivative IVd, obtained from Cyclosporin C, was subjected to physiological conditions similar to those found in the digestive apparatus (pH 1, THF/HCl). As shown in Figures 3 and 4, the cyclosporin was entirely reconstituted in 300 hours.

4.2 Preparation of hydrophilic derivatives

Attachment of a polymer that is highly water-soluble, such as the polyethylene glycol in the IIIb and IVh derivatives, suppressed the hydrophobic character of the initial cyclosporins (Cyclosporin A and C respectively.)

5. Biological activity of the cyclosporin derivatives of the present invention; inhibition effect on calf thymus Cyclophilin A.

The binding test described by Fisher et al. in *Biomed. Biochim. Acta, 1984* for cis-trans isomerases was applied to cyclophilin from calf thymus (3.8 nm), using the binding of Cyclosporin A as a reference. The values of the ratio IC_{50}/IC_{50CSA} are shown in the table below.

Derivatives	IIIb	IVa	IVb	IVc	IVd	IVe	IVf	IVg	IVh
IC_{50}/IC_{50CSA}	3.2	6	5.8	5.3	7.8	15.4	4	24.1	21.5

The curve for inhibition of cis-trans isomerase activity of Cyclophilin A by the derivative IVb is shown in Figure 5.

Surprisingly, despite the substantial modifications, such as steric modifications or fixing of the configuration of the peptide linkages, resulting from introduction of a pseudo-proline into the peptide moiety of Cyclosporins A or C that is assumed to bond to cyclophilin, there was no significant loss of activity in most of the derivatives, particularly for IIb, IVa-d and IVf. In fact, derivatives such as IVb, in which the pseudo-proline carries the highly hydrophobic biphenyl substituent, inhibit cyclophilin relatively strongly.

It is evident that the cyclosporin derivatives of the present invention possess highly interesting properties.

Specifically, the introduction of a pseudo-proline carrying appropriate substituents permits one or more of the following effects:

- improvement of the pharmacokinetic properties of cyclosporins by solubilisation in a physiological medium;
- production of "prodrugs" of the cyclosporins;
- introduction of reactive groups allowing crosslinking or labelling;
- modulation of the peptide conformation of the cyclosporins on account of steric constraints due to the five-membered ring, leading to modulation of the biological activity of the cyclosporins.

Claims

1. A cyclosporin derivative in which the peptide chain comprises at least one residue of a non-natural amino acid of general formula I:



(I)

in which

X denotes an oxygen or a sulfur;

R denotes a hydrogen, or an alkyl group having between 1 and 6 carbon atoms;

R_1 and R_2 denote, independently of each other, a hydrogen, an alkyl group, having between 1 and 6 carbons, which may be straight-chain or branched-chain, substituted or non-substituted, an alkylene group having between 1 and 6 carbon atoms, a substituted or non-substituted aryl group, a substituted or non-substituted heteroaryl group, a residue of a water-soluble polymer, possibly bound to a spacer group.

2. The derivative according to Claim 1, characterized in that, in the amino acid of general formula I, R denotes a hydrogen or a methyl group.

3. The derivative according to any of the preceding Claims, characterized in that it is derived from a cyclosporin in which the peptide chain contains at least one amino acid, chosen from serine, threonine and Sistine, in d or l configuration.

4. The derivative according to Claim 3, characterized in that at least one of the amino acids serine, threonine or Sistine of the basic cyclosporin is replaced by the amino acid of general formula I.

5. A method of preparation of the derivatives as in Claim 4, comprising an N,O-acetalisation reaction of at least one of the three amino acids serine, threonine and cysteine, by reacting the basic cyclosporin with a compound of formula II:



(II)

in which

Z_1 and Z_2 denote, independently of each other, a halogen, a hydroxyl group, an alkoxy group, or a thiol; or

both Z_1 and Z_2 together represent an oxygen of a carbonyl group or a sulfur of a thione; and

R_1 and R_2 are defined as above.

CsA
1. Ac_2O, DMAP, pyridine r.t., 18h.
2. a) OMe_3OBF_4, pyridine, DCM 0°C, 15h
b) $NaOCH_3$, MeOH r.t., 30%
1. NCS-Ph, DMAP, THF, r.t., 3h.
2. TFA/DCM r.t., 1h., 70%
3. 1. NCS-Ph, DMAP, THF, r.t., 3h
4. THF/DCM r.t., 1h. 70%
1. Fmoc-NMe-Leu-Thr(O-Ph-CONH-PEG750-pro)-OH
BOP-Cl, DIEA, DCM, r.t., 2h., 66%
2. NaOH, 16h., -5°C.
3. PyAOP, DIEA, 76%.
4. NaOH, MeOH, 15h., 75%
NH-Ph-PEG 750

Fig. 1


Fmoc
OBzl
HO
AllO
MeO
OMe
BF3-Et2O, toluene, 15 min., r.t.
OAll
Fmoc
OBzl
1. Pd(PPh3)4, EtSiH3, DCM, r.t., 72%
2. MeO-PEG750-NH2, PyBOP, DIEA, r.t., 98%.
3. H2, Pd-C, 5h., r.t., 88%
NH-PEG750
Fmoc
OBzl

Fig. 2



Fig. 3



Fig. 4



Fig. 5

2548-17
DPH 033 - US

RULE 63 (37 C.F.R. 1.63)
INVENTORS DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CYCLOSPORIN DERIVATIVES AND METHOD FOR THE PRODUCTION OF SAID DERIVATIVES

the specification of which (**check applicable box(s)**):

☐ is attached hereto
☐ was filed on _____ as U.S. Application Serial No. _____ (Atty Dkt. No. 2548-17)
☒ was filed as PCT international application No. PCT/IB00/00133 on 7 February 2000
and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

	Application Number	Country	Day/Month/Year Filed
☐	220/99	CH	5 February 1999
☐			

I hereby claim the benefit under 35 U.S.C 120/365 of all prior United States and PCT international applications listed above or below

Prior U.S./PCT Application(s):

Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned
PCT/IB00/00133	7 February 2000	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint **NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed)**, and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Larry S. Nixon, 25640; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31562; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32105; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoa, 37515; Raymond Y. Mah, 41426; Chris Comuntzis, 31097. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature: _____ Date: 27.07.01
Inventor: Manfred (first) MI MUTTER (last) German (citizenship)
Residence: (city) Préverenges (state/country) Switzerland
Mailing Address: Chemin de la Venoge 9, Préverenges, Switzerland CH
(Zip Code) CH-1028

2. Inventor's Signature: _____ Date: _____
Inventor: Roland (first) MI WENGER (last) Swiss (citizenship)
Residence: (city) Richen (state/country) Switzerland
Mailing Address: Grenzacherweg 45, Richen, Switzerland
(Zip Code) CH-4125

3. Inventor's Signature: _____ Date: _____
Inventor: Jean-François (first) MI GUICHOU (last) French (citizenship)
Residence: (city) Lausanne (state/country) Switzerland
Mailing Address: Université de Lausanne, Institut de Chimie Organique, Bâtiment de Chimie, Lausanne, Switzerland
(Zip Code) CH-1015

☒ ***See attached sheet(s) for additional inventor(s) information!!***

2548-17
DPH 033 - US

RULE 63 (37 C.F.R. 1.63)
INVENTORS DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CYCLOSPORIN DERIVATIVES AND METHOD FOR THE PRODUCTION OF SAID DERIVATIVES

the specification of which (**check** applicable **box(s)**):

☐ is attached hereto
☐ was filed on _____ as U.S. Application Serial No. _____ (Atty Dkt. No. 2548-17)
☒ was filed as PCT International application No. PCT/IB00/00133 on 7 February 2000
and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
220/99	CH	5 February 1999

☐ I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below.

Prior U.S./PCT Application(s):

Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned
PCT/IB00/00133	7 February 2000	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint **NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed)**, and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Larry S. Nixon, 25640; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam Jr. 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34778; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta 35329; Joseph A. Rhoa, 37515; Raymond Y. Mah, 41426; Chris Comuntzis, 31097. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature: _____ Date: _____
Inventor: Manfred (first) MI MUTTER (last) German (citizenship)
Residence: (city) Préverenges (state/country) Switzerland
Mailing Address: Chemin de la Venoge 9, Préverenges, Switzerland
(Zip Code) CH-1026

2. Inventor's Signature: _____ Date: 29.07.2001
Inventor: Roland (first) MI WENGER (last) Swiss (citizenship)
Residence: (city) Richen (state/country) Switzerland
Mailing Address: Grenzacherweg 45, Richen, Switzerland CH-4125
(Zip Code) CH-4125

3. Inventor's Signature: _____ Date: _____
Inventor: Jean-François (first) MI GUICHOU (last) French (citizenship)
Residence: (city) Lausanne (state/country) Switzerland
Mailing Address: Université de Lausanne, Institut de Chimie Organique, Bâtiment de Chimie, Lausanne, Switzerland
(Zip Code) CH-1015

☒ ***See attached sheet(s) for additional inventor(s) information!!***

2548-17
DPH 033 - US

Nixon & Vanderhye P.C. (10/99)
(Domestic Non-Assigned/Foreign) Page 1

RULE 63 (37 C.F.R. 1.63)
INVENTORS DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CYCLOSPORIN DERIVATIVES AND METHOD FOR THE PRODUCTION OF SAID DERIVATIVES

the specification of which (**check** applicable **box(s)**):

☐ is attached hereto
☐ was filed on _____ as U.S. Application Serial No _____ (Atty Dkt. No. 2548-17)
☒ was filed as PCT International application No. PCT/IB00/00133 on 7 February 2000
and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
220/99	CH	5 February 1999

☐ I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below:

Prior U.S./PCT Application(s): Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned
PCT/IB00/00133	7 February 2000	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint **NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed),** and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Larry S. Nixon, 25640; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178, Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoa, 37515; Raymond Y. Mah, 41426, Chris Comuntzis, 31097. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature: _____ Date: _____
Inventor: Manfred (first) MI MUTTER (last) German (citizenship)
Residence: (city) Préverenges (state/country) Switzerland
Mailing Address: Chemin de la Venoge 9, Préverenges, Switzerland
(Zip Code) CH-1028

2. Inventor's Signature: _____ Date: _____
Inventor: Roland (first) MI WENGER (last) Swiss (citizenship)
Residence: (city) Richen (state/country) Switzerland
Mailing Address: Grenzacherweg 45, Richen, Switzerland
(Zip Code) CH-4125

3. Inventor's Signature: J-F Guichou Date: 29.07.01
Inventor: Jean-François (first) MI GUICHOU (last) French (citizenship)
Residence: (city) Lausanne (state/country) Switzerland
Mailing Address: Université de Lausanne, Institut de Chimie Organique, Bâtiment de Chimie, Lausanne, Switzerland
(Zip Code) CH-1015

☒ ***See attached sheet(s) for additional inventor(s) information!!***

4. Inventor's Signature: Michael Keller Date: 8.8.2001

Inventor: Michael (first) MI KELLER (last) Swiss (citizenship)

Residence: (city) London (state/country) Great Britain (GBR)

Mailing Address: c/o A. Miller, Imperial College, Technology and Medicine, Dept. of Chemistry, London, Great Britain

(Zip Code) SW9 21Y

5. Inventor's Signature: Date:

Inventor: Thomas (first) MI RUCKLE (last) German (citizenship)

Residence: (city) Lausanne (state/country) Switzerland

Mailing Address: Université de Lausanne, Institut de Chimie Organique BCH, Lausanne, Switzerland

(Zip Code) CH-1015

6. Inventor's Signature: Date:

Inventor: Torsten (first) MI WOEHR (last) German (citizenship)

Residence: (city) Zürich (state/country) Switzerland

Mailing Address: Roeschibachstrasse 70, Zürich, Switzerland

(Zip Code) CH-8037

2548-17
Serial No.

4. Inventor's Signature: _____ Date: _____
Inventor: Michael (first) MI KELLER (last) Swiss (citizenship)
Residence: (city) London (state/country) Great Britain
Mailing Address: c/o A. Miller, Imperial College, Technology and Medicine, Dept. of Chemistry, London, Great Britain
(Zip Code) SW9 21Y

5. Inventor's Signature: Thomas Ruckle Date: 27/07/2001
Inventor: Thomas (first) MI RUCKLE (last) German (citizenship)
Residence: (city) Lausanne (state/country) Switzerland CH
Mailing Address: Université de Lausanne, Institut de Chimie Organique BCH, Lausanne, Switzerland
(Zip Code) CH-1015

500

6. Inventor's Signature: _____ Date: _____
Inventor: Torsten (first) MI WOEHR (last) German (citizenship)
Residence: (city) Zürich (state/country) Switzerland
Mailing Address: Roeschibachstrasse 70, Zürich, Switzerland
(Zip Code) CH-8037

2548-17
Serial No.

4. Inventor's Signature: _____ Date: _____
Inventor: Michael (first) MI KELLER (last) Swiss (citizenship)
Residence: (city) London (state/country) Great Britain
Mailing Address: c/o A. Miller, Imperial College, Technology and Medicine, Dept. of Chemistry, London, Great Britain
(Zip Code) SW9 21Y

5. Inventor's Signature: _____ Date: _____
Inventor: Thomas (first) MI RUCKLE (last) German (citizenship)
Residence: (city) Lausanne (state/country) Switzerland
Mailing Address: Université de Lausanne, Institut de Chimie Organique BCH, Lausanne, Switzerland
(Zip Code) CH-1015

6. Inventor's Signature: _____ Date: 30.07/2001
Inventor: Torsten (first) MI WOEHR (last) German (citizenship)
Residence: (city) Zürich (state/country) Switzerland CH
Mailing Address: Roeschibachstrasse 70, Zürich, Switzerland
(Zip Code) CH-8037

6